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Abstract 
The mechanism whereby fragments of streptokinase (SK) derived from  its N terminus (e.g., SK1-59 or SK1-63) enhance 
the low plasminogen (PG)-activating ability of other fragments, namely SK64-386, SK60-414, SK60-387, and SK60- 
333  (reported previously), has been investigated using a synthetic peptide approach. The addition of either natural SK1-59, 
or chemically synthesized SK16-59, at saturation (about 500-fold molar excess) generated amidolytic and PG activation 
capabilities  in  equimolar mixtures of human plasminogen (HPG) and its complementary fragment (either SK60-414 or 
SK56-414, prepared by expression of truncated SK gene fragments in Escherichia  coli) that were approximately 1.2- and 
2.5-fold, respectively, of that generated by equimolar mixtures of native SK and HPG. Although in the absence of SK1-59 
equimolar mixtures of SK56-414 and HPG could generate almost 80% of amidolytic activity, albeit slowly, less than 2% 
level of PG activation could be observed under the same conditions, indicating that the contribution of the N-terminal 
region lay mainly in imparting in SK56-414 an enhanced ability for PG activation. The ability of various synthetic pep- 
tides derived  from the amino-terminal region (SK16-51, SK16-45, SK37-59,  SK1-36, SK16-36, and SK37-51) to (1) 
complement equimolar mixtures of SK56-414 and HPG for  the generation of amidolytic and PG activation functions, (2) 
inhibit the potentiation of SK56-414 and HPG by SK16-59, and (3) directly inhibit PG activation by the 1:l SK-HPG 
activator complex was tested. Apart from SK16-59, SK16-51, and 16-45, the ability to rapidly generate amidolytic po- 
tential in  HPG  in the presence of SK56-414 survived even in the smaller SK-peptides, viz.,  SK37-59 and SK37-51. 
However, this ability was abolished upon specifically mutating the sequence -LTSRP-, present at position 42-46 in native 
SK. Although SK16-5 1 retained virtually complete ability for potentiation of PG activation in comparison to SK16-59 or 
SK1-59, this ability was reduced by approximately fourfold in the case of SK16-45, and completely abolished upon 
further truncation of the C-terminal residues to SK16-36 or SK1-36. Remarkably, however, these peptides not only dis- 
played ability to bind PG, but also showed strong inhibition of PG activation by the native activator complex in the mi- 
cromolar  range of concentration; the observed inhibition, however, could be competitively relieved by increasing the 
concentration of substrate PG in the reaction, suggesting that this region in  SK contains a site directed specifically toward 
interaction with substrate PG.  This conclusion was substantiated by the observation that the potentiation of PG activating 
ability was found to be considerably reduced in a peptide (SK25-59) in which the sequence corresponding to this putative 
locus (residues 16-36) was truncated at the middle. On the other hand, fragments SK37-51 and SK37-59 did not show any 
inhibition of the PG activation by native activator complex. Taken together, these findings strongly support a model of SK 
action wherein the  HPG binding site resident in the region 37-5 1 helps in anchoring the N-terminal domain to the  strong 
intermolecular complex formed between HPG  and the region 60-414. In contrast, the site located between residues 16  and 
36 is qualitatively more similar to the previously reported PG interacting site (SK254-273) present in the core region of 
SK,  in being involved in the relatively low-affinity enzyme-substrate interactions of the activator complex with PG during 
the catalytic cycle. 
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Streptokinase is a monomeric, multidomain protein of 47 kDa 
produced by several beta-hemolytic streptococci. Because of its 
potent PC activation property, SK  is widely used as a thrombolytic 
drug  for the treatment of several circulatory disorders, including 
myocardial infarction (ISIS-3, 1992). However, unlike other PC 
activators such as TPA and UK, a unique feature of SK action is 
that it has no proteolytic activity of its own, but forms a high- 
affinity equimolar complex with human plasminogen, which re- 
sults in the exposure of the cryptic active  site in HPG (reviewed by 
Castellino, 1981). As a consequence, the active site in HPG de- 
velops amidolytic and esterolytic potential even before the intro- 
duction of any proteolytic cleavage. This “virgin” enzyme complex 
is then converted rapidly to fully formed activator (either intact 
SK-HPG, as in the early phase after complex formation, or later, 
SK-HPN), which develops the capability to convert other “sub- 
strate” plasminogen molecules to plasmin by selective cleavage at 
the Arg560-Va1561 peptide bond (Markus & Werkheiser, 1964; Mc- 
Clintock & Bell, 1971; Reddy & Markus, 1972). Thus, the most 
intriguing aspects of the interaction of SK with HPG/HPN are (1) 
the structural basis of the activation of the cryptic active site in the 
zymogen, and (2) the conversion of this “nascent” activity to a 
highly specific proteolytic activity directed toward the scissile pep- 
tide bond in substrate PC. These issues are dramatically illustrated 
by the observation that, although HPN alone cannot activate PC to 
PN, its 1:l complexation with SK converts the active site in HPN 
(an enzyme, essentially with a trypsin-like specificity) to one  dis- 
playing a highly specific substrate preference. Clearly, an under- 
standing of the roles of various regions of SK in conferring these 
distinct biochemical functions into plasminogen/plasmin is impor- 
tant for the successful design of novel, second-generation SK- 
based thrombolytic drugs (Marder, 1993). 
Although the exact interplay of different domains in SK during 
the various stages of PC activation are far from clear at this stage, 
several recent studies employing truncated fragments of SK have 
focused on the regions in this protein that participate in the primary 
event in SK action, namely its avid binding to HPG. A high-affinity 
HPG binding site has been shown to be associated with the central, 
“core” region of SK, comprising approximately 150-200 of the 
total 414 residues of the full-length polypeptide (Nihalani & Sahni, 
1995; Reed et al., 1995; Rodriguez et a]., 1995). Several partial- 
length fragments containing this core region, e.g., SK60-333, 
SK147-380, SK64-380, have been observed to possess only very 
low levels of intrinsic PC activation ability despite the presence of 
significant amounts of native-like structure in the isolated frag- 
ments (Shi et al., 1994; Parrado et al., 1996). Thus, the exact 
manner in which the core HPG binding property of SK is struc- 
turally translated into PC activation and/or PN modulating func- 
tions still remains largely obscure. Interestingly, recent studies 
have demonstrated that a fragment corresponding to the N-terminal 
59 residues of SK could complement the low “PG activating ac- 
tivity” of polypeptide fragments derived from the remainder of the 
molecule, such as 60-387 and 64-380, to regenerate significant 
levels of the lost activator activity of the native protein (Shi et al., 
1994; Young et al., 1995; Parrado et al., 1996). However, it was 
noted that a large molar excess of the N-terminal fragment over the 
complementary fragment was required for optimal potentiation, 
indicating that the affinity between the two complementing part- 
ners, even in the presence of HPG, was relatively low (Shi et al., 
1994; Parrado  et al., 1996). 
Complementation between different fragments of a protein, lead- 
ing to the regeneration of biologically active, native-like com- 
plexes, has been demonstrated in selected systems in the past, most 
notably in the case of pancreatic ribonuclease and staphylococcal 
nuclease (reviewed in Anfinsen & Scheraga, 1975). The study of 
such “fragment complementing” systems provided fundamental 
insights regarding protein structural and functional aspects, partic- 
ularly as it also allows the development of semisynthetic proteins 
where one of the complementing partners is a chemically prepared 
mutant (Chaiken, 1981; Offord, 1987). It is notable, however, that 
most of the well-studied systems are comprised of enzymes wherein 
the optimal spatial configuration of key catalytic residues resident 
in the two different complementing partners could be brought about 
by native-like cooperative interactions between the complement- 
ing fragments, usually at equimolar proportions, despite the pres- 
ence of a discontinuity in the polypeptide backbone and/or overlap 
at the junctions of the fragments (Anfinsen & Scheraga, 1975; 
Blackburn & Moore, 1982). To draw a direct analogy with the case 
of SK, although no proteolytic activity is directly associated with 
the protein, the reconstitution of PC activating capability by two 
complementary fragments could conceivably result from a native- 
like re-orientation of two (or more) independent PC binding sites 
present in the fragments. This possibility appeared particularly 
alluring in view of our observations that a high-affinity HPG bind- 
ing site exists in and around residues 230-290 of SK, and another, 
albeit with relatively lower affinity, is present in the region 37-51 
of SK (Nihalani & Sahni, 1995; Nihalani et al., 1997). Keeping 
these considerations in mind, we sought to examine the nature of 
the contribution of the N-terminal region, particularly the HPG 
binding site present in the region 37-51, toward the generation of 
the fully functional activator complex. For this purpose, we pre- 
pared various truncated derivatives of the N-terminal region of SK 
through synthesis, and then examined their activation potential 
with HPG and a complementary fragment derived from the rest of 
the SK polypeptide. A similar approach, utilizing short synthetic 
peptides, has been used recently to map the main HPG binding site 
in SK (Nihalani et al., 1997). In the present investigation, we 
demonstrate a direct role of the N-terminal region in promoting 
substrate PC recognition by the activator complex. 
Results 
In order to define a suitable two-fragment complementing system 
for  SK that could be readily amenable to analysis employing chem- 
ically synthesized N-terminal fragments or their variants, we first 
studied natural SK1-59 prepared by limited tryptic digestion of 
Streptococcus equisimilis SK  (Nihalani et al., 1997)  and its exact 
complementary fragment (SK60-414). The latter was prepared by 
expression of a truncated SK gene lacking the codons  for the first 
59 residues in Escherichia coli (see the Materials and methods for 
details). However, the level of the expression of SK60-414 was 
poor (less than 5% of soluble intracellular protein). Despite this, 
we could purify SK60-414 in small quantities using HPG-agarose 
affinity chromatography (Rodriguez et al., 1992), allowing us to 
confirm that SKI-59, when added in excess over its complement- 
ing partner, could successfully potentiate the low basal PC acti- 
vating ability of SK60-414 (Fig. lA), as reported earlier (Young 
et al., 1995). However, for undertaking detailed studies, we re- 
quired much larger amounts of the complementing fragment. In 
our attempts to enhance the expression of SK60-414, it was ob- 
served that by merely extending four SK codons at the 5’-end of 
the open reading frame encoding SK60-414 (i.e., to obtain SK56- 
414), the level of expression of the polypeptide was increased 
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Fig. 1. A: HPG activating abilities of SK60-414 and SK56-414 in the absence and presence of SK1-59. The basal HPG-activating 
ability of recombinant SK-fragments (viz., SK56-414 or SK60-414), i.e., in the absence of SK1-59, was assayed by adding different 
concentrations (ranging from 0.1 to 0.5 p M )  of these fragments to excess HPG (2 p M )  in assay buffer containing chromogenic 
substrate in spectrophotometric cuvette as detailed in the Materials and methods. Activation of HPG to HPN was monitored at 405 nm. 
HPG activation in the presence of varying concentrations of SK1-59 (ranging from 0.1 to 2.5 pM) was also assayed similarly, by 
adding HPG (2 p M  final concentration) to the mixture of SK1-59 with either SK60-414 or SK56-414 (25 nM final concentration) 
and then measuring the PG activation as described above. Typical progress curves obtained from two different concentrations of 
SK60-414 (100 nM, cross in square; 200 nM, closed circles) or SK56-414 (100 nM, dot in square; 200 nM, open circles) in the 
absence of SK1-59 are shown. Also are shown the curves obtained as a result of potentiation of the basal activities of fixed 
concentration (25 nM in each case) of either SK60-414 (open triangles and open squares using 0.5 and 1.0 p M  of SK1-59, 
respectively) or SK56-414 (closed triangles and closed squares using 0.5 and 1.0 p M  of SK1-59, respectively). Control reaction in 
which no SK-fragment was added is depicted with crosses. All the values represent means obtained from four independent experiments. 
Inset: SDS-PAGE gel of the reagents used in the experiments. From left to right: lane 1, standard molecular weight markers, top to 
bottom: phosphorylase b (97.4 m a ) ,  BSA (66.2 m a ) ,  ovalbumin (42.7 m a ) ,  and trypsin inhibitor (21.5 kDa); lane 2, purified native 
SK; lane 3, purified human Glu-plasminogen; lane 4, purified SK60-414; lane 5,  purified SK56-414. B: Potentiation of the PG 
activator activity of SK56-414 by SK1-59 and SK16-59. The assay was performed under similar conditions as described above, 
except that varying concentrations (ranging from 2.5 to 10 p M )  of either SK1-59 or SK16-59 were added to fixed amounts of 
SK56-414 (0.1 pM).  The typical curves obtained using 0.1 p M  of SK56-414 and 2.5 p M  of SK16-59 (closed squares), 2.5 p M  
SKI-59 (open squares), 5 p M  SK16-59 (open circles), 5 p M  SK1-59 (open triangles), I O  p M  SK16-59 (closed circles), and 10 p M  
SK1-59 (closed triangles) are shown in the figure. Control reaction in which SK56-414 was omitted is depicted with crosses. All the 
curves are averages of at least four independent experiments (SD values, not depicted, were less than f 5%). 
dramatically, to approximately 30% of soluble intracellular pro- 
tein, thereby considerably facilitating the preparation of this frag- 
ment in quantities suitable for our studies. Natural SK1-59 could 
successfully potentiate the PC activating property of SK56-414, 
despite the three-residue overlap between the two fragments, in a 
manner indistinguishable from that observed with SK60-414 
(Fig. 1A). This result was not surprising, particularly because it 
has become clear from recent studies that the junction region be- 
tween the two  fragments probably exists in an inherently flexible 
state, a phenomenon that is reflected in its facile propensity to 
undergo selective proteolysis by different enzymes, and the ready 
isolation of fragments  such as 1-59 and 1-63, all of which could 
complement  core  fragments  such  as 64-380,  60-387,  60-293, or 
60-414 during PC activation (Shi et al., 1994; Nihalani & Sahni, 
1995; Young et al., 1995; Parrado et al., 1996). Therefore, in all 
subsequent experiments, the complementation observed with this 
two-fragment system (viz., SK1-59 and SK56-414) was used to 
compare and contrast the effects of controlled deletions/mutations 
in the N-terminal region of SK. 
The fragment SK56-414 was able to form an  equimolar  com- 
plex with HPG as observed by gel filtration (Fig. 2), which is in 
accord with the known presence of a high-affinity HPG binding 
site in the region 230-290 of SK (Nihalani et al., 1997). Likewise, 
SK1-59, which also contains an independent HPG binding site, 
albeit of lower affinity (Nihalani & Sahni, 1995), could also be 
seen to associate with HPG by gel filtration (Fig. 2). However, the 
association of SK1-59 with either SK60-414 or SK56-414, if 
any, could not be detected by this technique at a 1:l molar ratio 
(Fig. 2, profile f). From these results, it appears that a ternary 
complex forms between SK1-59,  SK56-414, and HPG during the 
potentiation reaction. 
Figure 3 shows the time-course of PC activation, as well as the 
amidolytic activity generated, by equimolar mixtures of SK or 
SK56-414 with HPG. In the case of native SK, both amidolytic 
and plasminogenolytic functions are generated rapidly, followed 
by a slow decline, presumably as a result of plasmin-mediated 
degradation. On the other hand, SK devoid of the N-terminal re- 
gion is a poor PC activator when mixed with the zymogen. This 
fragment, however, is able to generate significant (7540%) ami- 
dolytic activity in HPG, although slowly compared with full-length 
SK. It may be noted that the delay in the development of amido- 
lytic activity in the mixture of SK56-414 and HPG was not due to 
the delay in the complex formation because the association be- 
tween the two proteins could be visualized easily through gel- 
filtration after a brief preincubation of only 5 min (Fig. 2). Thus, 
the removal of the N-terminal region selectively affects PG acti- 
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Fig. 2. Binding of HPG to SKI-59 and SK56-414 as demonstrated by 
size-exclusion HPLC. The chromatography was performed on aTSK (32000 
SWXL (0.78 X 30 cm) column as described in the Materials and methods. 
Mixtures of HPG with either SKI-59 or SK56-414 and SK1-59 with 
SK56-414 were applied onto the column equilibrated in 0.1 M sodium 
phosphate buffer, pH 6.8, containing 10 mh4 6-aminohexanoic acid. The 
column was run at 250 pL/min and the absorbance of the eluant was 
monitored continuously at 210 nm as a function of time. Elution pro- 
files a, b, c, d, e, and f show positions of free HPG, free SKI-59, mixture 
of HPG and SKI-59, free SK56-414, mixture of HPG and SK56-414, and 
mixture of SKI-59 and SK56-414, respectively. 
vation, without a corresponding influence on the amidolytic capa- 
bility of the molecule. 
With the objective of defining possible cross-correlations be- 
tween primary structural elements in the N-terminal region of SK 
and its PC activation and amidolytic potentiating properties, we 
required a facile system whereby we could  generate several trun- 
cated versions of SKI-59, and then examine their ability to po- 
tentiate the basal PC activation and amidolytic capability of 
equimolar mixtures of SK56-414 and  HPG. It is known that the 
first 15 residues of SK can be truncated without adversely affecting 
its PC activating properties (Malke et al., 1987) because these 
residues play a role in the secretion of this protein from the host 
cell (Pratap et al., 1996). This observation encouraged us to ex- 
plore the synthetic peptide route, especially because moderate- 
length peptides can be routinely synthesized chemically with 
relatively high fidelity. This avenue became quite attractive when 
the synthetic peptide SK16-59 (lacking 15 residues from the 
N-terminal of SKI-59 observed to be nonessential in native SK) 
was found to be able to potentiate the  HPG activating ability of 
SK56-414 essentially in a manner identical to that of SK1-59 
(Fig. 1B). We then prepared several truncated peptides derived 
from the 16-59 region of SK, viz., SK16-51, SK16-45, and 
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Fig. 3. Generation of amidolytic and activator activities in HPG upon 
complexation with SK or SK56-414. An equimolar mixture of SK or 
truncated SK-fragment SK56-414 with HPG (500 nM each) was prepared, 
and the amidolytic activity as well as the activator activity generated in the 
complex was assayed periodically. The increase in activator and amidolytic 
activities of SK-HPG complex as a function of preincubation are shown by 
closed circles and closed squares, respectively, and those of SK56-414- 
HPG are represented by open triangles and open squares, respectively. The 
activity generated by equimolar SK56-414 and HPG was compared with 
the maximum activity generated by the (SK-HPG) native activator com- 
plex (taken as 100%) to calculate the percent increase in activity. The 
control reaction, without SK or SK56-414, is depicted with open circles. 
Mean values from four independent experiments are shown. SDs are shown 
by vertical error bars. 
SK16-36 with the objective of specifically examining the effect of 
truncation of SK16-59 in  the region of its C terminus, where a pro- 
posed HPG binding sequence (LTSRPA) is present (position 42-46) 
(Gonzalez-Gronow et al., 1993; Nihalani & Sahni, 1995). We also 
synthesized the peptide SK37-59 derived from  this region, as well 
as its shorter derivative (SK37-51), which has been shown previ- 
ously to bind to HPG (Nihalani & Sahni, 1995), in  order to closely 
examine the significance of this site in SK-HPG interaction. 
The potentiation of the amidolytic and PC activator activities of 
SK56-414 by truncated N-terminal peptides are presented in Fig- 
ures 4 and 5, respectively. These  data reveal that the presence of 
saturating concentrations of either SK16-59 or SK16-51 (which 
display essentially identical potentiating properties) could reverse 
the loss of PC activator activity of SK brought about by the re- 
moval of the N-terminal domain. Surprisingly, the PC activator 
activity of SK56-414 could be raised twofold over that of native 
SK in the presence of a saturating level of SK16-59 (Fig. 5 ) ;  the 
exact basis for this “superactivation” is presently unclear, but is 
probably not a phenomenon unique to the two-fragment system, 
because the addition of the N-terminal fragment to the native SK- 
HPG complex also resulted in the enhancement of the maximal 
activator activity attained (see Fig. 5). Because the addition of a 
similar excess of natural SKI-59 to native SK also caused “su- 
peractivation” (Fig. 5), it  is  clear that this phenomenon is not an 
offshoot of the  use of synthetic peptides. In the case of amidolysis, 
where the effect of truncation of the N-terminal residues resulted 
not so much in a loss of activity (approximately 75% compared 
with SK) as a delayed attainment of full amidolytic potential 
(Fig. 3), the kinetics of the generation of amidolytic function was 
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Fig. 4. Enhancement of the amidolytic activity of equimolar SK56-414 
and HPG by N-terminal SK-peptides. Various concentrations of each SK 
N-terminal peptides (ranging from 0 to 500 p M )  were added to SK56-414 
(500 nM) and equimolar  amounts of HPG. Amidolytic activity generated 
over time in SK56-414-HPG complex was then followed spectrophoto- 
metrically. Amidolytic activity generated (using saturating concentration of 
peptide that showed maximum increase in the activity) was compared with 
that generated in equimolar HPG by native SK (closed small squares; 
indicated by "SKI in the  legend), taken as  loo%, to calculate the percent 
activity in each case. Various SK-peptides used in the reaction, as indicated 
in the legend, were: SK16-59 (100 pM),  closed triangles; SK16-51 
(100 pM), small open triangles; SK16-45 (300 pM). closed large squares; 
SK37-59 (300 pM),  closed circles; and SK37-5 1 (350 pM),  open circles. 
Control-I, where no SK-peptide was added, is shown as open squares, 
whereas control-2, in which neither SK-peptide nor SK56-414 was added, 
is depicted with dot in square. Amidolytic activity of HPG in the presence 
of SK56-414, and a mutant peptide derived from the SK37-59 fragment 
(see text for details) is shown as  dots. All the values are averages of four 
independent measurements. 
brought about to virtually the same level as that shown by full- 
length SK. However, in the presence of saturating concentrations 
of either SK16-59 or 16-51, the peak activity attained was ap- 
proximately 20% above that of native SK. A kinetic analysis re- 
vealed that this could be ascribed to an enhanced rate of catalysis 
(Table 1) without a concomitant change in the apparent affinity for 
the amidolytic substrate (the K, of SK56-414 in the absence and 
presence of SK16-59 was essentially unchanged). On the other 
hand, as shown in Table 2, the intrinsically low catalytic efficiency 
(kplg/Kplg) of SK56-414 for PG activation was enhanced by the 
presence of the complementing fragment by nearly 1,400-fold, but 
only about 3-fold in terms of amidolytic functioning (cf. Table 1). 
The increase in PG activation rates due  to the presence of saturat- 
ing  concentrations of SK16-59 was reflected both in terms of a 
decreased K,,,  for HPG as well as increased V, for catalysis of 
HPG to HPN. From these data, it can be concluded that the 
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Fig. 5. Potentiation of HPG activator activity of equimolar SK56-414 and 
HPG complex by N-terminal SK-peptides. The increase in HPG activator 
activity of SK56-414-HPG complex with time was measured by adding 
different N-terminal SK-peptides (saturating concentrations of each pep- 
tide was used) to SK56-414 (500 nM) and equimolar amounts of HPG and 
monitoring the activation reaction spectrophotometrically. The percent ac- 
tivity in each case is shown relative to the maximum activator activity 
generated in equimolar HPG by native SK (depicted with closed squares; 
indicated by " S K  in the legend), taken as 100%. The various N-terminal 
SK-peptides, as indicated in the legend, added to the potentiation reaction 
containing equimolar HPG and SK56-414, were: SK16-59 (100 pM). 
closed triangles; SK16-51 (100 pM), small open triangles; SK16-45 
(300 pM),  closed large squares; SK37-59 (300 pM),  closed circles; 
SK37-51 (350 pM), small open circles; and SK1-36 (500 pM),  cross in 
square. Control reaction in which SK56-414 was excluded is represented 
by dots in squares. Enhancement in the activator activity of the SK-HPG 
complex by 5 p M  of either SK16-59 (large closed triangles) or SKI-59 
(large open circles) is also shown. The HPG activator activity of SK56- 
414 in the presence of SK-peptide SK25-59 (in which the region SK16-36 
was truncated) is represented by dots. Data shown are the means and SDs 
of quadruplicate determinations. 
N-terminal region of SK (residues 16-59) plays a major role in 
augmenting the low PG activator activity associated with the rest 
of the molecule. 
The results of the experiments with the PG activator and ami- 
dolysis enhancing potential of the truncated derivatives of SK16-59 
showed that shortening of SK16-59 to SK16-51 had virtually no 
effect on either amidolytic or PG activating capabilities of the 
N-terminal fragment. However, further deletion at the C-terminal 
end, to obtain SK16-45, resulted in a very perceptible alteration in 
both of these properties. The kinetics of amidolysis, as well as PG 
activation, were considerably slower with SK16-45; in quantita- 
tive terms, 60-70% reduction in the potentiation of amidolytic and 
Table 2. Steady-state kinetics parameters for the activation 
of HPG by SK and SK-fragments 
Table 1. Steady-state kinetics parameters for the amidolytic 
activity of HPG with SK and SK-fragments KPC 
Activator 
kPk 
(uM) (min") (min- uM ') 
kPlPl/KPk- 
SK/SK-fragment (d) (s") (s" m"') SK-HPG 0.23 f 0.01 4.40 f 0.20 19.0 
SK56-414-HPG 1.00 k 0.05 0.05 ? 0.005 
SK 
0.05 
SK56-414 0.92 k 0.08  173 f 12 188 + SK16-59 0.15 f 0.01 7.00 f 0.30 46.7 
K m  kcar kcatlKm 
0.61 f 0.05 374 f 10  613 SK56-414-HPG 
SK56-414 + SK16-59 0.55 f 0.05 374 f 18 680  SK-HPG+SK16-59 0.11 f 0.01 4.56 k 0.22 41.5 
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PG activator activities at saturation, in comparison to the full- 
length fragment, was observed. The effect of deletion of these 
particular residues was also reflected in the HPG binding ability of 
these N-terminal SK-peptides. This binding was performed by spe- 
cific assays, viz., dot-blot and ELISA (Fig. 6A.B). Although the 
dot blots served as a qualitative screening procedure, the relative 
affinities of the different peptides with HPG were determined by 
ELISA. In the case of SK16-59 and SK16-51, their binding with 
HPG was found to be almost similar (Kd = 3.8 f 0.5 X and 
thus comparable to that of SKI-59, reported previously through 
analyses of the ELISA binding isotherms (Nihalani & Sahni, 1995). 
However, the truncation of SK16-59 to SK16-45 resulted in ap- 
proximately IO-fold reduction in HPG binding of this fragment 
Upon complete truncation of the HPG binding region, as in the 
fragment 16-36, the ability to potentiate PG activation in SK56- 
414 was completely lost [no detectable increase was observed even 
at a concentration of 500 pM, compared to the control, viz., equi- 
molar (500 nM) mix of SK56-414 and HPG]. This fragment was 
also inactive with respect to enhancement in the kinetics/extent of 
potentiation of amidolysis by SK56-414. However, the HPG bind- 
ing curves (Fig. 6A.B) showed that SK16-36 possessed HPG bind- 
ing ability (Kd = 2.5 f 0.5 X comparable to that displayed 
by SK37-51 (Nihalani & Sahni, 1995). In order to test whether the 
( K d  = 5.0 k 0.2 X IO-'). 
* D  
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observed loss in potentiating ability in SK16-36 was  due to con- 
formational destabilization brought about by reduction to a very 
short length rather than an actual truncation of an epitope per se, 
we synthesized SKI-36, with an extended length at the N-terminal 
side. However, this fragment also could not potentiate amidolysis 
or PG activation by SK56-414. Derivatives of SK16-59 with 
truncation at the N-terminal end, but with the C-terminal se- 
quences preserved, viz., SK37-59 and SK37-51, also could not 
enhance  the PG activation by SK56-414 beyond the basal 3-4% 
levels compared to that of native SK. By contrast, these fragments 
were efficient in promoting nearly full potentiation of amidolysis 
by SK56-414 (Fig. 4), although at relatively higher concentrations 
compared with SK16-59 or SK16-51. Moreover, in the presence 
of the saturating concentrations of these peptides (i.e., SK37-59 
and SK37-5 I), the generation of full amidolytic activity in SK56- 
414 was rapid (i.e., 10-20 min) compared with SK56-414 alone, 
which was able to generate 75% amidolytic activity in HPG after 
45 min of preincubation (Fig. 4). The role of this segment (residues 
SK37-59) in enhancing amidolysis was then tested by examining 
a mutant peptide (SK37-59). altered specifically in primary struc- 
ture at a proposed HPG interacting site (Gonzalez-Gronow et al., 
1993; Nihalani & Sahni, 1995) by altering the sequence LTSRP, at 
position 42-46, to AAAAA. This peptide displayed no amidolytic 
enhancing ability (Fig. 4). demonstrating the involvement of this 
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Fig. 6. HPG binding of SK  or SK-peptides as determined by dot blot and C 0.8 ELISA. A: Dot  blot showing binding of different amounts of each N-terminal 
SK-peptides (20 pg to 2.5 pg)  to '"I-labeled HPG. Positions 1-6 corre- 
spond  to SK-peptides, viz.,  SK16-59,  SK16-51, SK16-45, SK16-36,  SK37- 
59. and SK37-SI, respectively, whereas the position marked 7 represents a 
0.6 control peptide derived from the primary structure of SK16-36.  but in 
which the sequence was randomly scrambled. Positions A, B, C, and D 
correspond to 20, IO, 5,  and 2.5 pg of each peptide blotted onto nitrocel- 
lulose by serial dilution. B: Quantitative ELISA for HPG binding. The 
figure shows binding of SK (closed squares), SK16-59 (closed triangles), 
E 
In 
0 0.4 
r2 SK16-51 (small open triangles), SK16-45 (closed large squares), SK16-36 
U (large open triangles), SKI-36 (small open squares), SK37-59 (closed 
0.2 Control reaction where SK  or SK-peptide was omitted is shown as dot in  
circles), SK37-59 mutant peptide (dots), and SK37-51 (open circles) with 
HPG as determined by ELISA using polyclonal antisera specific for HPG. 
square. Data is representative of four independent experiments. C: Com- 
petition of SKI-36 peptide with either SK37-.59 or SK254-273 for HPG 
binding. SKI-36 ( 1 0 0  pM per well) was covalently immobilized onto 
ELISA plate. The ability of varying amounts (0-100 pM) of either SK254- ' 273 (closed circles) or SK16-S9 (closed triangles) to inhibit the binding of 
immobilized SKI-36 to HPG was then tested. The competition of SK16-59 
PEPTIDE (uM) with SK37-59 (open squares) for HPG binding is also shown. Three inde- 
pendent experiments gave the same result and the typical one is shown here. 
0.0 
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region in the generation of amidolysis in HPG by SK. Thus,  two 
distinct epitopes/structural units in the N-terminal region seem to 
be responsible for the potentiation of the activity of the central 
domain of SK mediated by the N-terminal domain. The  epitope 
assisting the potentiation of amidolysis essentially could be iso- 
lated to a small segment (SK37-51). The potentiation of PC acti- 
vation by  SK16-59, however, required both this C-terminal segment 
as well as sequences contained in the region 16-36, because pep- 
tides devoid of this region were also, on their own, unable to 
potentiate the PC activation effectively. When the peptides repre- 
senting these two regions, i.e., SK16-36 and SK37-59 (in equi- 
molar amounts), were added simultaneously to equimolar mixtures 
of HPG and SK56-414, no further enhancement in HPG activation 
(beyond a basal 4% relative to SK-HPG) was observed even at 
very high molar excess of SK1-36 and SK37-59, indicating that 
the continuity in the peptide backbone is also required between the 
two segments to bring about fruitful complementation with SK56- 
414 (data not shown). 
Although the fragment SK16-36 was inactive in the promotion 
of PC activation by the complementary fragment, it was of interest 
to examine if it could inhibit the potentiation displayed by the 
fragments SK16-59 or SK16-51 (both with relatively high PC 
activating abilities). Results of potentiation-inhibition experiments 
performed with these and other truncated fragments derived from 
the segment 16-59 of SK indicated that only SK16-36 (as also 
SK1-36) was highly efficient in showing this inhibition (the in- 
hibitory concentration of peptide causing 50% inhibition, i.e., 
ICs0 = 13 * 1 pM), with marginal inhibition also shown by 
SK16-45 (data not shown). Remarkably, both of these peptides 
could also effectively inhibit the PC activation by the SK-HPG 
activator complex (ICs0 = 15 f 2 pM for SK16-36 and 25 f 
2 pM for SK16-45) (Fig.  7). A kinetic analysis of this inhibition 
indicated that it arose specifically from a fourfold alteration of the 
K,,, of the SK-HPG activator complex for substrate PC (raised from 
0.2 pM to 0.8 pM) in the presence of inhibitory concentrations 
(20 pM) of SK16-36 and SK16-45 (50 pM) (Fig.  7, inset). As a 
corollary to this observation, the inhibition by a fixed concentra- 
tion of either SK16-36 or SK16-45 could be smoothly reversed 
by simply increasing the substrate PC in the reaction (data not 
shown). These results strongly pointed to the presence of  an epitopel 
conformation in the region 16-36 of the activator complex that 
interacted specifically with molecules of substrate PG.  The impor- 
tance of this putative region in substrate PC activation was further 
established by synthesizing a peptide, SK25-59, which lacks the 
first nine residues of SK16-36. The ability of this peptide to po- 
tentiate the activator activity of SK56-414-HPG complex was 
reduced to barely 5-10% compared with the SK-HPG complex 
(Fig. 5). However, as expected from the presence of the region 
37-59 in this peptide, the amidolysis enhancing potential was fully 
preserved in this peptide (data not shown). 
Recently, we have reported the presence of a region in the high- 
affinity core PC binding site of SK (identified as residues 234-293 
by Peptide Walking) that displays specific binding to substrate PC 
molecules (Nihalani  et al., 1997). A synthetic peptide based on this 
sequence (viz., SK254-273) was found, in a manner similar to that 
observed here with SK1-36/SK16-36, to competitively inhibit PC 
activation by SK-HPG, and also to increase the K, of the activator 
complex for PC (Nihalani  et al., 1997). In order to examine if this 
substrate PC-binding  epitope present in the N-terminal region of 
SK displayed antagonism/additivity/synergy with the substrate PG- 
binding site present in the core region of the protein, we performed 
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Fig. 7. Inhibition by N-terminal SK-peptides of substrate PG activation by 
SK-HPG activator complex. Preformed equimolar SK-HPG complex 
(10 nM) was added to HPG (1 pM) in the assay buffer containing various 
concentrations of N-terminal SK-peptides (0-300 pM). HPG activation 
was measured spectrophotometrically. Percent inhibition due to either 
SK16-36 (closed circles) or SK16-45 (open triangles) was calculated from 
the rates of plasmin generated in the presence of peptides compared with 
that in the activation reaction (taken as 100%) where no peptide was added. 
The control reaction where no SK was added is depicted with closed 
triangles. Inset: Lineweaver-Burke plot for the determination of kinetic 
parameters for HPG activation by SK-HPG complex in the presence of 
N-terminal SK-peptides. The experiment was performed under identical 
conditions as mentioned above, except that the concentration of  HPG  in the 
reaction was varied from 0.035 to 3.0 pM. The control reaction, in which 
no peptide was added, is depicted with closed circles, whereas reactions 
where either SK16-36 or SK16-45 were included are shown as closed 
triangles and open triangles, respectively. Qualitatively similar results were 
obtained when BPG instead of HPG was used as a substrate. Data are 
representative of four independent experiments performed in duplicates. 
inhibition experiments using mixtures of the two peptides, which, 
when used individually, brought about a certain defined level of 
inhibition (25-50%) in PC activation by SK-HPG. The results 
(Table 3) clearly showed that the inhibitory influence of both these 
peptides was additive. To further examine if these two sites bound 
with HPG independently of each other, competitive ELISA was 
performed. The results presented in Figure 6C show that, unlike 
SK-peptide SK16-59, SK254-273 was unable to compete with 
SK16-36 for HPG binding. This indicated that the binding of the 
region 16-36  of SK with HPG occurred at a site distinct from that 
of the region 254-273, present at the core of the high-affinity HPG 
binding site. 
Discussion 
One of the principal conclusions that emerges from our fragment 
complementation studies is that the amino-terminal fragment- 
mediated potentiation of PC activation by SK56-414 and  HPG  is 
affected in a much more dramatic manner than that of the poten- 
tiation of amidolytic capability. The potentiation of PC activation 
by SK56-414 is almost completely dependent on the presence of 
the N-terminal fragment (either SK1-59, SK16-59, or SK16-51). 
It may be noted that a very large molar excess of the N-terminal 
SK-fragment  was  required to generate full HPG activating/ 
amidolytic ability at saturation. This result, although surprising at 
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a b l e  3. Inhibition of activator activity of SK-HPG 
activator complex  by  combination of SKI636 
and SK254273 SK-peptides 
Percent inhibitiona by 
individual  SK-peptidesb Percent  inhibition‘ 
upon combination of 
SK16-36  SK254-273 both the SK-peptides 
22 15 
15 
40 f 2 
35  45 f 2 
40 15 50 k 1 
30  40  65 k 3 
‘Different  concentrations of the peptides that showed the desired  inhi- 
bition of substrate F’G activation individually were  added  simultaneously in 
the  activator  assay to obtain  the  additive  effect.  Percent inhibition in each 
case was calculated by comparison  with the control (taken as 100%) where 
no  peptide was added. 
the  negative  control  reaction, an HPG binding  SK-peptide,  SK234- 
253, but which did not show any significant inhibition of substrate PG 
activation  on  its  own,  was  chosen (100 WM final concentration). When this 
peptide was added to either SK16-36 or SK254-273 in the inhibition 
assays, the inhibitory effect of only SK16-36 or SK254-273 could be 
observed  and  no  additive  effect  could  be  detected. 
‘Data  represent the mean of four independent experiments. 
first sight, has also been noted previously (Shi et al., 1994; Parrado 
et al., 1996). A plausible explanation for this was forwarded by 
Parrado et al. (1996), based upon their CD and NMR studies of the 
isolated domains of SK. They suggested that the N-terminal region 
of SK, when isolated in solution, remains largely in an unstruc- 
tured conformation. Therefore, we speculate that the majority of 
the unfolded molecules are unable to associate with the remainder 
of the SK molecule, whereas only a minority population with a 
native-like conformation can do so. Thus, in such a situation, a 
large increase in the overall concentration in the N-terminal frag- 
ment would be required to “push” the equilibrium more toward 
complex formation. This supports our finding that, at a 1 : 1 molar 
ratio, the two complementary fragments are unable to associate 
with each other, whereas, at a fivefold molar excess of the N-terminal 
fragment, some association could be detected by gel filtration 
(Conejero-Lara et al., 1996). The fact that several hundred-fold 
molar excess of the N-terminal fragment is required to obtain a 
saturating level of PC activating ability even in the potentiation 
reactions suggests that the inherently weak affinity between the 
two isolated fragments is not substantially overcome by the pres- 
ence of HPG, although each of the two complementary fragments 
possesses independent HPG binding ability. 
In contrast to the PC activating ability, the ability to generate 
nearly 75% of amidolytic capability in HPG, although slower com- 
pared with native SK, already exists in SK56-414, despite the 
truncation of the N-terminal region. Remarkably, the ability to 
potentiate the amidolytic activity was found to  be fully preserved 
even in the small fragments corresponding to the C-terminal region 
of SK16-59 (viz., SK37-59 and SK37-51). In contrast, the ability 
to potentiate the PC activator activity in  these fragments (SK37-59 
and SK37-51) was very low. Thus, the principal role of the 
N-terminal region of SK  in terms of generating amidolytic poten- 
tial in the activator complex seemed to be localized in and around 
residues 37-51  of the polypeptide. Interestingly, a stretch of amino 
acid sequence present in the segment 37-5 1 (LTSRPAH), has also 
been shown to be present in the P C  binding domain of human 
fibronectin (Gonzalez-Gronow et al., 1993). A Ser residue in this 
sequence undergoes ATP-mediated phosphorylation through a re- 
action autocatalyzed by the SK-HPN complex; as a result, the 
amidolytic activity of the activator complex is decreased signifi- 
cantly (Serrano et al., 1996), strongly indicating the contributory 
role of this PG binding region in  the catalytic functioning of the 
molecule. Our  experiments  show that truncation in the 37-51 re- 
gion in the N-terminal fragment (to obtain SK16-45 or SK16-36) 
drastically reduces the ability of this region to potentiate PC acti- 
vation in SK56-414. Thus, our findings that the mutation of the 
“target” sequence in SK37-59 (LTSRP) to Ala residues (as well as 
the earlier report that the phosphorylation of Ser-44 in native SK) 
virtually completely abolished the ability of this region to bring 
about amidolytic potentiation of SK56-414 and HPG is rationally 
consistent with the conclusion that the HPG binding site between 
residues 37 and 51 of SK  is important for the functioning of the 
molecule, particularly in the rate of generation of amidolytic ca- 
pability by the activator complex. 
In contrast to the fragments SK16-59 and SK16-51, fragments 
SK1-36 or SK16-36 could not themselves bring about any poten- 
tiation either of PC activation or amidolysis, showing that, for PC 
activation as well, the presence of the sequence in and around 
residues 37-5 1 of SK  is important. It is particularly revealing that 
neither SK16-36, SK1-36, SK37-59, or SK37-51 individually, 
nor mixtures of  SK1-36  and  SK37-59, could effectively potentiate 
the basal PC activator activity of SK56-414. Nevertheless, SK1-36 
or SK16-36 were  able to efficiently inhibit PC activation by the 
native activator complex (SK-HPG) in the micromolar range of 
concentration. This suggests that an “epitope” existed in the region 
16-36 of the N terminus of SK that might be participating in 
conferring substrate specificity to the activator. The fact that po- 
tentiation of PG activation was significantly reduced in SK16-45, 
in which partial truncation of the SK37-59 HPG binding site had 
occurred, and completely abolished in SK16-36, points strongly 
toward the requirement for the simultaneous presence of both sites 
in one contiguous peptide unit for optimal complementation by the 
N-terminal region. Indeed, this conclusion is validated by the ob- 
servation that no potentiation of PG activation could be seen with 
SK25-59 also (a fragment in which the putative PC interacting site 
between residues 16  and 36 would have been truncated) but which, 
nevertheless, retained complete amidolytic potentiating function. 
Clearly, the presence of a discontinuity between these two epitopes 
(16-36 and 37-5 1 )  would immediately imperil the functioning of 
the substrate activation reaction because the “substrate gathering” 
epitope would lose the necessary anchoring with the rest of the 
activator complex (a property presumably provided by SK37-51). 
Thus, a peptide such as SK1-36, bearing only the substrate PG- 
specific function, when added in excess into PC activation reac- 
tions catalyzed by SK-HPG, strongly inhibits the reaction, probably 
by binding with substrate PC and competing with the correspond- 
ing epitope in the N-terminal portion of the SK moiety of the 
activator for binding with substrate, a scenario entirely consistent 
with our observation that the Kplg of SK-HPG  is raised severalfold 
in the presence of SK1-36. On the other hand, the inclusion of 
SK1-59 or SK16-59 in excess to PC activation reactions catalyzed 
by SK-HPG results in an apparent “superactivation” of the latter. 
We propose that SK1-59, which possesses both the “anchoring” 
and substrate binding functions, provides a transient “bridge” be- 
tween the activator complex and substrate PC and, hence, en- 
hances the overall rate of PG activation (this scenario presupposes 
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that a dynamic  exchange  is possible between the N-terminal region 
of the  native  complex  and the externally added SK1-59). Although 
entirely speculative at present, the  fact that the Kplg values of both 
native  SK-HPG  and SK56-414-HPG actually decrease by nearly 
twofold in the presence of SK16-59 (Table 2) lends support to this 
possibility. However, additional factors,  such as stabilization of the 
activator complex by the N-terminal region (as proposed by 
Conejero-Lara et al., 1996; Parrado et al., 1996), or its ability to 
compensate for the loss of this region from  the activator complex 
and  the consequent loss of activity (Siefring & Castellino, 1976) 
may also play a role in the twofold superactivation phenomenon, 
particularly if the presence of an excess of the externally added 
fragment  allows, at saturation, a level of PC activator activity to be 
attained that would not be possible in even the native SK-HPG 
complex because of the degradation of this region. 
It is  quite intriguing that at least three clearly demarcated loci in 
SK  are involved in the interaction of this protein with HPG (see 
Fig. 8). Although the locus present in SK16-37 has been detected 
for  the  first time, the PC binding properties of the regions 37-51 
and 234-293 of SK  have been shown earlier (Nihalani & Sahni 
1995; Nihalani et al., 1997). Although the function associated with 
the region 37-51 is only now becoming clear, the high-affinity 
HPG binding site present in residues 234-293 recently has been 
shown to constitute a principal intermolecular contact region be- 
tween SK and HPG during the formation of the l :  l SK-HPG 
activator complex  (Nihalani et al., 1997). Remarkably, this region 
appears to bind in the close vicinity of the active site in HPG/HPN, 
and  contains a site (residues 254-273) that, like the one present in 
the region 16-36, binds selectively with substrate PG. However, 
the results obtained in the present study through the competitive 
ELISA experiments demonstrate that peptides SK16-36  and SK254- 
273 do not compete with each other for HPG binding, indicating 
that each is directed at its cognate site in substrate PG that is 
sterically distinct from the other. It therefore appears quite likely 
that each of these sites participates independently of the  other  in 
interacting with substrate PC. The observations reported earlier, 
that specific alterations in these two regions, viz., a change of 
Gly-24 to a bulkier residue, such as  Glu or His (Lee et al., 1989), 
or the modification of critical lysine residues (viz., Lys-256,257 to 
alanines) (Lin et al., 1996) substantially reduced the PC activation 
properties of SK, strongly lend support to our finding that both 
binding sites are intimately involved in substrate recognition. Such 
a two-point attachment, indeed, could be the reason why the pep- 
tides bearing these two substrate PC-specific loci, viz., SK16-36 
and SK254-273, show an additive influence in their inhibition of 
the PC activation by pre-formed activator complex. 
The results obtained in the present study, together with those of 
studies  in  the  recent past (Shi et al., 1994; Nihalani & Sahni,  1995; 
Parrado et al., 1996; Serrano et al., 1996; Nihalani et al., 1997), 
now permit us to tentatively propose the following model of SK 
action, at least in terms of the principal mechanistic events in- 
volved. Upon complex formation, the N terminus of SK, which is 
covalently attached to the main chain, becomes anchored to the 
rest of the SK-HPG complex through the PC binding site present 
in the region 37-51. All of these interactions, together with the 
high-affinity intermolecular interaction of HPG and SK mediated 
by the  core binding region (i.e., in  and around residues 234-293) 
of the latter, as well as the resultant conformational changes in the 
zymogen, cause the exposure of the active  site  in  the complexed 
HPG. In the native SK-HPG complex, this rapidly results in the 
activation of the HPG to HPN. However, the transformation of 
SK-HPG to SK-HPN, by itself, does not confer PC activation 
ability onto the activator complex, but requires additional struc- 
tural inputs to engender the characteristic substrate preference as- 
sociated with the fully functional activator. Our studies show that 
this  is conferred by the concerted action of the two substrate PG- 
specific sites resident in the sequences 16-36 and 254-273, both 
probably acting cooperatively to sequester substrate (PC) selec- 
tively at the active site during the catalytic cycle. Thus,  it is prob- 
ably this interplay of the three PG binding loci of SK, rather than 
a direct change of the enzymatic specificity by interference at the 
secondary binding subsites of the active site of the complexed 
plasmin/plasminogen, that brings about the remarkable alteration 
in substrate preference consequent to SK binding. Of course, this 
description does not necessarily discount the involvement of other, 
as yet unidentified, contacts between SK and HPG, and/or be- 
tween SK-HPG/HPN and substrate PC, that might also play struc- 
tural roles in the functioning of the activator complex. Virtually all 
of the recent studies  on the mechanism of SK action have focused 
on identifying primarily the sites in SK that are responsible, first, 
for the formation of the strong 1 : 1 equimolar complex with HPG, 
followed by the highly specific but transient interaction between 
the activator complex and substrate PC during which the scissile 
peptide bond in the zymogen is cleaved. However, the relatively 
more subtle, but nevertheless important questions regarding the 
dynamics/structural processes responsible for the sequential re- 
lease of the product (plasmin)  at the end of each catalytic cycle 
deserves close scrutiny as well. These and several other funda- 
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REGION  I REGION 11 
Fig. 8. Schematic representation of the different HPG-interacting sites in SK. The two regions, I and I1 (spanning residues 16-51 and 
234-293), involved in the interaction of  SK with P G ,  are shown. Region I (residues 16-51) has a bifunctional character. The locus 
resident between SK37-51 (shaded) is important for PG activation because it likely tethers the N-terminal portion of SK with the 
SK-HPG complex even in the absence of a continuity between peptide bond 59-60; the locus SK16-37 contains an epitope that 
possesses specificity for substrate PG. Region I1 (shaded areas) is primarily involved in the formation of the high-affinity equimolar 
complex with HPG; it encompasses a smaller locus (residues 254-273) that, like the one present in the N-terminal region (SK16-37), 
imparts additional substrate specificity to the complex. The cooperative action of both the substrate PG specific loci (depicted as dark 
areas in Regions I and 11) in sequestering substrate PG to the active site probably results in the high PG activation rates associated with 
the native activator complex. 
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mental issues can now be addressed more precisely by undertaking 
detailed mutational analyses of the regions in SK identified by 
physico-chemical approaches to play major roles in its functioning. 
Investigations along  these  lines  are currently in progress. 
Materials  and  methods 
Reagents 
Highly pure streptokinase from S. equisimilis H46 A was a kind 
gift from Dr. R.A.G. Smith (Smith-Kline Beecham, U.K.). It dis- 
played a specific activity of 120,000 I.U./mg protein measured by 
the procedure of Jackson et al. (1981)  using chromogenic peptide 
substrate; protein was determined according to Bradford (1976). 
The preparation showed a single band on SDS-PAGE (see Fig. lA, 
inset). The human Glu-plasminogen used in our kinetics experi- 
ments was procured from Boehringer-Mannheim (Germany). As- 
says using synthetic peptide substrate showed all batches to contain 
less than 0.01 % of free plasmin, which was in accordance with the 
supplier’s specifications. The number of active sites generated in 
HPG (used for the enzymatic assays) was determined by active- 
site titration using the acylating agent, p-nitrophenyl guanidino- 
benzoate as described for SK by McClintock and Bell (1971). In 
experiments where stabilizer-free HPG was needed, as in the gel 
filtration and dot blot experiments, we purified the HPG from fresh 
citrated human plasma collected in the presence of protease inhib- 
itors by the standard procedure of Deutsch and Mertz (1970), 
which consistently gave plasminogen with less than 0.02% of plas- 
min. The chromogenic plasmin substrate and BPG were procured 
from Sigma Chemical Co. (St. Louis, Missouri). Thermostable 
DNA polymerase (pfu)  for PCR was obtained from Stratagene Inc. 
(Germany). All other reagents used were of the highest purity 
available. The expression vector T7 PET-23 (d) was obtained from 
Novagen, Inc. (Wisconsin). The N-terminal SK-fragment, SK1-59, 
was prepared by limited proteolysis of SK by trypsin as described 
(Nihalani & Sahni, 1995). The synthetic N-terminal SK-peptides 
were custom synthesized by Chiron Mimotopes, Australia. Crude 
synthetic peptides were purified by RP-HPLC on preparative C-18 
Vydac columns  (250 mm X 10  mm) using relatively shallow ace- 
tonitrile gradients  in 0.1% TFA. Their purities (ranging from 70 to 
85%) were established through analytical microbore RP-HPLC 
and ion-spray mass spectroscopy. Quantitation of the peptides was 
performed by amino acid analysis after PITC derivatization (Find- 
lay & Geisow, 1989). 
Construction and purification of truncated SK derivatives 
The complete structural gene of streptokinase from S. equisimilis 
H 46 A (as a 2.5-kb Pst I fragment), along with its flanking reg- 
ulatory regions, was first cloned into plasmid vector pBR322 in 
E. coli, essentially according to the procedure of Malke and Fer- 
retti (1984) (see also Pratap et al., 1996  for  details regarding con- 
struction of SK-containing vectors). The SK gene (as a Nco I- 
BamH I fragment) was then transferred from the vector, pJKD-57, 
to pET-23d, the T7 promoter-based expression vector (Studier, 
1991)  and  also to pBluescript I1 KS- (Stratagene Inc.)  at  the single 
EcoR V site after T4 DNA-polymerase catalyzed fill-in of the 
insert using standard methodologies (Sambrook et al., 1989). The 
latter construct (pBluescript containing the SK gene) was used as 
the template for the generation of truncated SK genes by PCR, 
whereas the SK-containing expression vector, pET-23d-SK, was 
used for the cloning of the PCR products and expression of 
N-terminally truncated SK polypeptides, viz., SK60-414 and SK56- 
414. The open reading frame coding  for SK60-414 was prepared 
by, first, pfu DNA polymerase-catalyzed PCR using specific primers 
(upstream primer: 5’-TCAAAACCATTTGCTACTGATAGTGGC- 
3’; downstream  primer: 5”AATATAGGCTAAATGATAGCTA 
GCATTCTCTCC-3’). The  cycling conditions for denaturation, an- 
nealing, and extension used during PCR reaction were 95 “C for 
45 s, 55 “C for 1 min, and 72 “C for 1 min, respectively, and were 
performed for 25 cycles, after which 10 min at 72°C were pro- 
vided before termination of the reaction. This DNA (encoding for 
residues 60-384 of SK) was then digested with BsrG I, at a unique 
site resident around nucleotide 1388 (numbered according to Malke 
et al., 1985) of the sequence of the Pst I fragment. This corre- 
sponds approximately to residue 1 6 4  of the primary structure of 
mature SK. The digested fragment was agarose gel-purified, and 
then cloned into PET-23d-SK pre-digested with Nco I followed by 
a fill-in reaction with T4 DNA polymerase, and then treated with 
BsrG I to make it compatible for ligation with the PCR product 
(containing a blunt terminus at one end and a cohesive terminus, 
produced by BsrG I, at  the  other).  The ligation of this fragment 
with the digested SK-containing PET-23d recreates the original 
open reading frame of SK in the expression vector, but one that 
now begins with a deletion corresponding to 59 N-terminal resi- 
dues. Construction of SK56-414 was performed similarly using an 
upstream primer (5’-TTAAGTCCAAAATCAAAACCATTTGC 
TACT-3’) encoding four additional amino acid residues at the 5‘ 
end, and the  same downstream primer as in the case of SK60-414, 
described above. After transformation of E. coli strain BL-21 
(Studier, 1991) and selection of positive colonies by restriction 
analysis of plasmid DNA, the inserts were sequenced by the di- 
deoxy method (Sanger et al., 1977). For the production and puri- 
fication of desired proteins, the bacterial cells containing the target 
gene were induced with 1 mM IPTG in their mid-log phase of 
growth and were harvested after 3 h of further incubation at 37 “C. 
The cells were lysed by sonication, centrifuged, and the super- 
natant diluted 10-fold with 50 mM Tris-C1 buffer, pH 7.5, con- 
taining 100 mM NaCl. The level of expression of SK60-414, as 
analyzed by SDS-PAGE, was found to be less than 5% of the total 
intracellular soluble protein, whereas that of SK56-414 was found 
to be more than 25% (data not shown). In the case of SK60-414, 
where protein expression was  low, single-step purification by affinity 
chromatography using HPG-agarose was performed (cf. Fig. 1 A, 
inset), essentially as described for SK (Rodriguez et al., 1992). 
SK56-414 was purified as follows. To the diluted bacterial lysate 
containing SK56-414, NaCl (to a final concentration 2.0 M)  was 
added, and the solution loaded onto a 25-mL bed-volume phenyl- 
Sepharose column (Pharmacia Ltd.) pre-equilibrated with buffer 
(50 mM Tris-C1, pH 7.5) containing 2 M NaCI. The column was 
then washed with the equilibration buffer (10 bed-volumes) fol- 
lowed by 50 mM Tris-C1 buffer, pH 7.5 (5 bed-volumes). The 
bound protein was eluted with sterile distilled water and made 
25 mM in Tris-C1, pH 7.2; it was then loaded onto a 25-mL 
DEAE-Sepharose Fast Flow (Pharmacia) ion-exchange column pre- 
equilibrated with the  same buffer. Elution was performed by ap- 
plying a linear gradient of 0-0.3 M NaCl (50 mL each) in buffer. 
All chromatographic steps were conducted at 4°C. The fractions 
containing protein were analyzed on SDS-PAGE along with stan- 
dard SK and MW markers. Desired fractions were pooled conser- 
vatively to obtain the homogenous preparation of SK56-414 
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(Fig. lA, inset). Apart from gene sequencing, the authenticity of 
SK56-414 and SK60-414 was also established by gas phase 
N-terminal amino acid sequencing of both proteins on  an Applied 
Biosystems-Perkin Elmer protein sequencer model 476-A. 
HPG activator activity of SK56-414 in  the absence 
and presence of either SKI-59 or SKI&-59 
The HPG activating ability of recombinant SK-fragments (viz., 
SK60-414 or SK56-414) in the absence of N-terminal SK- 
peptides was assayed by adding various concentrations of these 
fragments (ranging from  0.1 to 0.5 p M )  to assay cuvette contain- 
ing assay buffer [50 mM Tris-C1 buffer, pH 7.5, containing 0.5 mM 
chromogenic  substrate (Tosyl-Gly-Pro-Lys-pNA) and 0.1 M NaCI] 
and excess  HPG (2  pM).  The activation of HPG to HPN, resulting 
in the hydrolysis of chromogenic substrate, was monitored by 
continuously recording the change in absorbance at 405 nm in a 
Shimadzu UV-160 model spectrophotometer at 22°C for 10 min. 
In the control reaction, no SK60-414 or SK56-414 was added. 
The HPG activating ability of these SK-fragments in the presence 
of various concentrations of either SK1-59 or SK16-59 (0.1- 
2.5 p M )  was also assayed by employing 25 nM of either SK60- 
414  or SK56-414 as described above. 
Size-exclusion HPLC to demonstrate binding of SKI-59 
and SK56-414 to HPG 
The chromatography was performed at 22 "C using an ABI-Perkin 
Elmer model 172  HPLC system fitted with a TSK (32000 SWXL 
column (0.78 X 30 cm). The column was equilibrated in 0.1 M 
sodium phosphate buffer, pH 6.8, containing 10 mM 6-amino- 
hexanoic acid, and the flow was kept at 250 pL/min. Mixtures of 
HPG (2.7 p M )  with SK1-59 (2.7 pM) or SK56-414 (3.0 pM) 
were preincubated for 5 min in the presence of 2 mM NPGB and 
50 p L  were then applied onto  the column. Similarly, a mixture of 
SK1-59 (2.7 p M )  with SK56-414 (3.0 p M )  was also loaded onto 
the column after a preincubation of 5 min. The absorbance of the 
eluant was monitored continuously at 210 nm as a function of time. 
Assay for the generation of amidolytic activity in HPG 
by SK and SK-fragments in  the absence and 
presence of N-terminal SK-peptides 
Equimolar complexes of HPG with either SK, SK60-414, or SK56- 
414 (final concentration, 0.5 p M  of each component) in the ab- 
sence or presence of various concentrations of different N-terminal 
SK-peptides (ranging from 20 to 500 pM) were incubated at  22 "C 
for different time intervals (0-120 min) in dilution buffer. Aliquots 
were transferred periodically to measure the amidolytic activity 
generated in the complexes by adding them to  100-pL assay cu- 
vette containing assay buffer (final concentration of complex, 
0.15 pM). The change in absorbance was measured as described 
previously. In the control reaction, no SK, SK60-414, or SK56- 
414 was added. 
Amidase parameters of complexes of HPG with SK 
or SK56-414 in the presence of SKI&-59 
Equimolar  HPG (final concentration 0.5 pM) was added to either 
SK, SK56-414, or SK56-414 containing 100 p M  of SK16-59 in 
50 p L  of dilution buffer (50 mM Tris-C1 buffer, pH 7.5, con- 
taining 0.5% BSA), and the mixture was incubated at 22°C. 
Aliquots of 15 p L  each from these mixtures were then with- 
drawn at specified times (2 min for  SK  and SK56-414 contain- 
ing SK16-59 and 45 min for SK56-414, depending upon the 
maturation of the complex, where maximal amidolytic activity 
was observed) and added to assay cuvette (100-pL total vol- 
ume) containing various concentrations of chromogenic substrate 
(0.06-2.0 mM) in assay buffer. The change in absorbance was 
monitored spectrophotometrically at 405 nm for 10 min. Kinetic 
parameters  for amidolysis  were then determined from the 
Lineweaver-Burke plots (Radek et al., 1993). 
Assay for determining the steady-state kinetic constants for 
HPG activator activity in complexes of HPG with SK or 
SK56414  in  the presence and absence of SK16-59 
HPG was mixed with either SK (500 nM) or SK56-414 (5 p M )  
in equimolar amounts in dilution buffer and incubated at  22 "C for 
2 min and 30 min, respectively. Aliquots from this mixture were 
then added to the assay cuvette (final concentration 10 nM for the 
SK-HPG complex, and 0.5 p M  for the SK56-414-HPG complex) 
containing assay buffer and various concentrations of HPG (0.05- 
3.0 pM) (Radek et al., 1993). The rate of HPG activation was 
monitored spectrophotometrically by recording the increase in rate 
of release of p-nitroanilide from the chromogenic substrate by the 
HPN generated as a result of HPG activation. For determining the 
kinetic constants for HPG activator activity in the presence of 
N-terminal SK-peptides, 100 p M  or 5 p M  of SK16-59 was added 
to SK56-414 or SK, respectively, followed by the addition of 
equimolar amounts of HPG (final concentration 500 nM with re- 
spect to SK or SK56-414) to the mixture. After incubation at 22 "C 
for 10 min in the case of SK and 30 min for SK56-414, aliquots 
from these mixtures were added to assay cuvette (final concentra- 
tion of SK-HPG or SK56-414-HPG complex,  10 nM) containing 
assay buffer and various concentrations of HPG (ranging from 
0.05 to 3.0  pM). The rate of HPG activation was monitored as 
described above. The kinetic parameters for HPG activation, Kprn 
(the apparent Michaelis constant for HPG as substrate) and kprn 
(the catalytic rate constant of activator) were calculated by the 
construction of Lineweaver-Burke plots, as described (Wohl et al., 
1980). 
Potentiation of  the  HPG activator activity of SK56-414-HPG 
complex by N-terminal SK-peptides 
Various peptides corresponding to the N-terminal of SK were added 
at different concentrations (ranging from 0 to 500 p M )  to SK56- 
414 (0.5 pM) in dilution buffer and incubated at 22°C for 2 min. 
HPG (final concentration, 0.5 p M )  was then added to the mixtures 
and incubated further at 22°C for various time intervals (0- 
60 min). Periodically, aliquots were removed and assayed for HPG 
activator activity by adding to assay cuvette (final concentration of 
SK56-414-HPG complex 10 I") containing assay buffer and 
2 p M  of HPG. The HPG activation was followed as described 
previously. In positive-control reactions, either 0.5 p M  of equi- 
molar SK-HPG  complex or SK-HPG complex containing 5 p M  of 
either SK1-59 or SK16-59 were taken, whereas the negative- 
control reaction contained SK N-terminal peptides without SK or 
SK56-414. 
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Analysis of binding of N-terminal SK-peptides  with HPG 
by  dot-blot and EUSA 
Dot-blot and ELISA were performed as described previously (Ni- 
halani & Sahni, 1995). Briefly, for dot-blot analyses, varying 
amounts of N-terminal SK-peptides (prepared by twofold serial 
dilution, and ranging from 25 to 2.5 pg)  were adsorbed onto 
nitrocellulose and probed with '251-labeled HPG. The relative bind- 
ing affinities of each peptide with reference to  SK were determined 
by ELISA using polyclonal HPG-specific antiserum as described 
previously (Nihalani & Sahni, 1995). 
Assay for determining the inhibition of activator activiry 
of SK-HPG complex by N-terminal SK-peptides 
The assay was performed essentially as described previously (Ni- 
halani et al., 1997). Briefly, an equimolar SK-HPG complex 
(500 nM) was formed by preincubating SK and HPG in dilution 
buffer for 2 min at 22°C. An aliquot from this mixture was then 
added to assay cuvette (final concentration of SK-HPG complex, 
10 nM) containing various concentrations of individual peptides 
(0-300 pM) and 1.0 pM of either BPG or HPG  in the assay buffer. 
The activation of PG  to  PN was monitored as described previously. 
The extent of inhibition of substrate PG activation by different 
concentrations of peptides was expressed as a percentage relative 
to a control reaction (taken as 100%), where no peptide was added. 
For determination of the kinetic parameters of substrate PG acti- 
vation by activator complex in  the presence of SK-peptides, the 
assay was performed as described above, except that the concen- 
tration of peptides used in the assay cuvette was 20 pM, and 
varying concentrations of either BPG or HPG (0.25-3.0 pM)  were 
used in the assay buffer. The kinetic parameters for PG activation 
were calculated by standard methods (Wohl et al., 1980). 
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